Overview

Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B

Status:
Completed

Trial end date:
2005-09-01

Target enrollment:

Participant gender:

Summary

The primary objective of this clinical research study is to establish the bioequivalence of 2 treatments, rFIX and rFIX-R, when given as a 10-minute intravenous bolus infusion.

Phase:

Phase 3

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer